Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Patient characteristics
Characteristics 
No. 100
 Male 60
 Female 40
Age (mean) (yr) 11.9 ± 5.5
Primary diagnosis (No.) (%) 
 Hematologic malignancy 65, 65%
  Acute myeloid leukemia 34, 34%
  Acute lymphoblastic leukemia 17, 17%
  Hodgkin lymphoma 8, 8%
  Myelodysplastic syndrome 5, 5%
  Anaplastic large-cell lymphoma 1, 1%
 Hematologic disorder 5, 5%
  Severe aplastic anemia 3, 3%
  Sickle cell disease 2, 2%
 Solid tumor 28, 28%
  Neuroblastoma 15, 15%
  Ewing sarcoma 9, 9%
  Germ cell tumor 3, 3%
  Desmoplastic small round cell tumor 1, 1%
 Immune disorder 2, 2%
  Severe combined immunodeficiency 1. 1%
  Wiskott-Aldrich syndrome 1, 1%
Transplant donor (No.) (%) 
 Allogenic 66, 66%
 Autologous 34, 34%
Disease status at transplantation (No.) (%) 
 Complete remission 82, 82%
 Active disease 18, 18%
T-cell depletion (No.) (%) 2, 2%
GVHD II–IV (No.) (%) 15, 15%

Characteristics
No.	100
Male	60
Female	40
Age (mean) (yr)	11.9 ± 5.5
Primary diagnosis (No.) (%)
Hematologic malignancy	65, 65%
Acute myeloid leukemia	34, 34%
Acute lymphoblastic leukemia	17, 17%
Hodgkin lymphoma	8, 8%
Myelodysplastic syndrome	5, 5%
Anaplastic large-cell lymphoma	1, 1%
Hematologic disorder	5, 5%
Severe aplastic anemia	3, 3%
Sickle cell disease	2, 2%
Solid tumor	28, 28%
Neuroblastoma	15, 15%
Ewing sarcoma	9, 9%
Germ cell tumor	3, 3%
Desmoplastic small round cell tumor	1, 1%
Immune disorder	2, 2%
Severe combined immunodeficiency	1. 1%
Wiskott-Aldrich syndrome	1, 1%
Transplant donor (No.) (%)
Allogenic	66, 66%
Autologous	34, 34%
Disease status at transplantation (No.) (%)
Complete remission	82, 82%
Active disease	18, 18%
T-cell depletion (No.) (%)	2, 2%
GVHD II–IV (No.) (%)	15, 15%